The EDC3 Knockout NCI-H1975 Polyclonal Cells constitute a CRISPR/Cas9-edited polyclonal knockout cell population with targeted disruption of the EDC3 gene in the NCI-H1975 human lung adenocarcinoma cell line. This heterogeneous population preserves a spectrum of loss-of-function alleles generated by CRISPR/Cas9-mediated gene disruption, enabling functional interrogation of EDC3 without clonal selection bias. The product is provided as a ready-to-use polyclonal knockout model for studying post-transcriptional gene regulation in cancer biology.
NCI-H1975 is a well-characterized human non-small cell lung cancer (NSCLC) model derived from the pleural effusion of a female patient with adenocarcinoma. The cell line harbors activating EGFR L858R and the secondary T790M gatekeeper mutations, rendering it clinically relevant for studying EGFR-targeted therapy resistance. As an adherent epithelial line, NCI-H1975 is widely employed to investigate oncogenic signaling, drug response, and tumor biology, providing a disease-relevant background for dissecting the role of mRNA decay factors.
EDC3 functions as a scaffold protein that enhances the activity of the DCP1-DCP2 decapping complex, a central component of the 5??-3?? mRNA decay pathway. It directly interacts with decapping cofactors DCP1A, DCP2, PNRC2, and additional P-body components including DDX6, LSM14A, and EDC4 to stimulate removal of the 5?? mRNA cap. Following decapping, the exoribonuclease XRN1 degrades the transcript body processively. EDC3 thus coordinates assembly of the decapping machinery and facilitates coupling of deadenylated mRNAs to destruction. Its activity is modulated by stress signals and upstream regulators such as DCP1A, DCP2, and PNRC2, while its downstream consequences influence the stability of target mRNAs and assembly of P-bodies, cytoplasmic foci where mRNA triage and decay occur.
In the context of EGFR-mutant lung adenocarcinoma, dysregulation of mRNA turnover can contribute to oncogenic phenotypes and drug sensitivity. Knockout of EDC3 disrupts normal decapping activity, leading to stabilization of specific mRNAs encoding proliferation regulators, survival factors, or stress-responsive proteins. The polyclonal population provides a robust loss-of-function system to examine EDC3-dependent changes in gene expression without confounding clonal artifacts. By using these cells, researchers can explore how altered mRNA decay kinetics impact signaling pathways downstream of mutant EGFR and influence responses to tyrosine kinase inhibitors or chemotherapy.
This knockout model supports diverse experimental applications, including measurement of mRNA half-life by actinomycin D or metabolic labeling, RNA-seq transcriptome profiling to identify EDC3-regulated transcripts, RT-qPCR quantification of candidate mRNAs, and western blotting to assess protein level changes. Immunofluorescence microscopy can visualize P-body abundance and composition, while co-immunoprecipitation assays track integrity of the decapping complex. Cell viability and drug sensitivity assays in the knockout background enable investigation of EDC3??s role in therapeutic response. For further information or technical support, please contact Ascent Research.
